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Background: Hospital performance is being benchmarked increasingly against surgical indicators such as 30-day
mortality, length-of-stay, survival and post-surgery complication rates. The aim of this paper was to examine
oesophagectomy rates and post-surgical outcomes in cancers of the oesophagus and gastro-oesophageal junction
and to determine how the addition of gastro-oesophageal cancer to oesophageal cancer impacts on these
outcomes.
Methods: Our study population consisted of patients with a primary invasive oesophageal or gastro-oesophageal
cancer identified from the NSW Cancer Registry from July 2000-Dec 2007. Their records were linked to the hospital
separation data for determination of resection rates and post-resection outcomes. We used multivariate logistic
regression analyses to examine factors associated with oesophagectomy and post-resection outcomes.
Cox-proportional hazard regression analysis was used to examine one-year cancer survival following
oesophagectomy.
Results: We observed some changes in resection rates and surgical outcomes with the addition of
gastro-oesophageal cancer patients to the oesophageal cancer cohort. 14.6% of oesophageal cancer patients and
26.4% of gastro-oesophageal cancer patients had an oesophagectomy; an overall oesophagectomy rate of 18.2% in
the combined cohort. In the combined cohort, oesophagectomy was associated with younger age, being male and
Australian-born, having non-metastatic disease or adenocarcinoma and being admitted in a co-located hospital.
Rates of length-of-stay >28 days (20.9% vs 19.7%), 30-day mortality (3.8% vs 2.7%) and one-year survival
post-surgery (24.5% vs 23.1%) were similar between oesophageal cancer alone and the combined cohort; whilst
30-day complication rates were 21.5% versus 17.0% respectively. Some factors statistically associated with
post-resection complication in oesophageal cancer alone were not significant in the overall cohort. Poorer
post-resection outcomes were associated with some patient (older age, birthplace) and hospital-related
characteristics (fiscal sector, area health service).
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Conclusion: Outcomes following oesophagectomy in oesophageal and gastro-oesophageal cancer patients in NSW
are within world benchmarks. Our study demonstrates that the inclusion of gastro-oesophageal cancer did alter
some outcomes compared to analysis based solely on oesophageal cancer. As such, care must be taken with
analyses based on administrative health data to capture all populations eligible for treatment and to understand
the contribution of these subpopulations to overall outcomes.
Keywords: Hospital outcomes, Oesophageal cancer, Administrative health data, Data linkageBackground
Accountability and transparency in health care, at indi-
vidual and institutional levels, has gained increasing
importance in recent years [1-3]. This growing focus
on quality of practise and safety of services has implica-
tions for patients, clinicians, administrators and policy
makers. Quality assessments of hospital performance are
now conducted routinely throughout the world, the
results of which are made available to all stakeholders.
Information of this kind has been used for the purposes
of benchmarking, so as to improve performance across
all institutions [4] and to empower the general public
to make informed decisions about where they choose to
receive care.
Surgical resection for curable oesophageal and gastro-
oesophageal cancer is the mainstay of treatment for all
patients who are fit for major surgery. However, despite
being the only curative treatment for oesophageal/
gastro-oesophageal cancer patients, oesophagectomy is
associated with significant operative morbidity and mor-
tality [5-7]. Key performance measures of oesophagect-
omy include 30-day mortality, hospital length-of-stay and
post-surgery complication rate [8-17]. Factors influencing
outcomes following oesophagectomy include hospital/
surgeon factors (peer group/volume, surgical experience),
tumour stage, histology and location, surgery type and
patient comorbidity; with better outcomes reported in
high volume hospitals, patients with non-metastatic dis-
ease (approximately 60% of patients), adenocarcinoma
(the incidence of which is increasing), and when transhia-
tal oesophagectomy is performed [18-25].
In Australia, there has been keen interest in using
administrative datasets to examine hospital performance
[26-28] with surgeons, administrators and patients having
endorsed independent review of surgical care [29]. We
previously examined patient outcomes for oesophageal
cancer following oesophagectomy in one Australian state
using data linkage of administrative datasets [9]. We
found oesophagectomy was performed with satisfactory
outcomes however resection rates were lower than
reported elsewhere, as other studies included cancer of
the gastro-oesophageal junction in their analyses since
gastro-oesophageal cancer is treated in a similar manner
to oesophageal cancer [30,31].Therefore, our aim was to examine rates of oesopho-
gectomy and post-resection outcomes for patients diag-
nosed with oesophageal cancer or gastro-oesophageal
cancer in the state of New South Wales (NSW) between
2000 and 2007. Specifically, we examined the way in
which the inclusion of gastro-oesophageal cancer to the
oesophageal cancer cohort impacted on resection rates
and post-resection outcomes.Methods
Setting
Australia has a publicly-funded universal health care
system and health care data is collected by Common-
wealth and state-based jurisdictions. The Australian
Government Department of Human Services administer
the Medicare Benefits Scheme (MBS; which provides
free or subsidised treatment by health professionals and
fully subsidised treatment in public hospitals) and the
Pharmaceutical Benefits Scheme (PBS; which provides
subsidised access to prescription drugs). The individual
state and territory health authorities are responsible
for the collection of public and private hospital separ-
ation data within their jurisdiction. However, cross-
jurisdictional data sets have not been linked routinely
due to legislative and privacy issues.
Our current study uses routinely collected hospital
separation data from New South Wales (NSW). NSW is
the largest jurisdiction in Australia with eight area health
districts (at the time this research commenced) and
consists of more than 200 public and 80 private hospitals,
some of which are in proximity to each other (co-
located). As such medical specialists practise at both the
public and affiliated private hospital.
Study population
Our study population consisted of patients with a pri-
mary invasive oesophageal and gastro-oesophageal can-
cer (International Classification of Diseases v3 [ICD-O-3]
codes C15.0-C15.9 and C16.0).
Data sources and linkage
We accessed and linked two population-based data sets
in this study:
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(CCR) receives notifications of cancer in NSW and
maintains a record of all cancer cases diagnosed in NSW
residents since 1972. The registry is managed according
to the International Association of Cancer Registries
(IACR) rules [32] and is one of the few Australian Cancer
Registries to record degree-of-spread at first diagnosis
for all solid malignant tumours [33]. Degree-of-spread is
assigned by the NSW CCR into one of four summary
stages (localised, regional, distant or unknown) [25].
Histology type was based on Berg groupings of ICD-O-3
classifications and grouped as adenocarcinomas, squa-
mous cell carcinoma (SCC) or other.
Admitted Patient Data Collection (1 July 2000 – 30 June
2008) - is a census of all inpatient separations from all
public, private and repatriation hospitals, private day pro-
cedures centres and public nursing homes in NSW. We
identified surgical resections in the separations using the
International Classification of Diseases (ICD_10_AM)
procedural block codes for oesophagectomy by abdom-
inal and thoracic/cervical/transthoracic mobilisation and
endoscopic mucosal resection 0858–0860 (if recorded)
[34].
Data linkage was undertaken by a third-party, the
NSW Centre for Health Record Linkage (CHeReL) using
best practice privacy preserving protocols. Using probabil-
istic linkage, CHeReL identified all appropriate records
from the APDC and CCR. They then assigned unique
identifiers (or Project Person Number: PPN) to the APDC
and CCR files. We received two individual data files and
linked the unit-record data using the unique PPNs.Outcomes measures and statistical analyses
We reported oesophagectomy rates for oesophageal
cancer, gastro-oesophageal cancer and the combined
cohort. As oesophagectomy is most beneficial for, and
is associated with, non-metastatic disease and patients
with adenocarcinoma, we also examined rates of surgical
resection and factors associated with surgical resection
and post-surgical outcomes for this sub-group of patients.
Multivariate logistic regression was used to determine
which factors were associated with (i) receiving an oeso-
phagectomy and (ii) the post-resection outcomes of:
longer length of hospital stay (>28 days); 30-day compli-
cation and 30-day mortality. Post resection complications
arising within 30 days were derived from ICD-10-AM
diagnostic codes and included any post-procedural dis-
orders or complications, haemorrhages, pulmonary and
cardiac complications.
Cox proportional hazard regression survival analysis was
also undertaken to examine one-year survival following
oesophagectomy. We followed patients diagnosed with
oesophageal cancer or cancer of the gastro-oesophagealjunction in the NSW CCR to 31st December, 2007 for
death from the cancer.
We did not identify individual hospitals in this study,
rather we grouped hospitals by health service (identified
as Area 1 – Area 8) and according to fiscal sector (public
co-located; private co-located; public non co-located;
private non co-located). We used the Charlson Comor-
bidity Index (CCI) to account for comorbidity before
cancer diagnosis [35]. This index is commonly used to
adjust for comorbidity and was derived from ICD-10-
AM diagnostic codes as recorded in any hospital separ-
ation prior to and including the date of cancer diagnosis
[36,37]. Other covariates of interest included patient
factors of age at diagnosis, gender, Australian or overseas
born, tumour location and surgical procedure (where
appropriate).
Statistical significance was taken at the p<0.05 level.
All statistical analysis was performed using SAS
version 11.
Ethical approval
This research was approved by the NSW Population and
Health Service Research Ethics Committee (2010/05/235).
Results
Cohort Characteristics (Table 1)
Our cohort comprised 5,024 patients, 3,456 (69%) of
whom were diagnosed with oesophageal cancer and
1,568 with gastro-oesophageal cancer.
More than half of oesophageal cancer patients were
≥70 years, 67% were male, 45% were diagnosed with
adenocarcinoma, 20% with regional spread and 18% with
distant spread-of-disease. The vast majority (90%) of
oesophageal cancer patients were defined by the CCI as
having no pre-existing comorbidity. Similarly, most
gastro-oesophageal patients were ≥70 years and male.
Owing to the nature of gastro-oesophageal cancer, 89%
of this group were diagnosed with adenocarcinoma, 35%
with regional and 25% with distant disease spread. The
addition of gastro-oesophageal patients to the cohort
increased the proportion of patients in the overall cohort
with adenocarcinoma to approximately 60%, and patients
with regional or distant spread increased from 38% to
45%.
Rates of surgical resection and factors associated with
receiving surgical resection (Tables 2,3)
The rate of resection in oesophageal cancer patients
was 14.6%, whereas 26.4% of gastro-oesophageal patients
underwent surgical resection. The addition of gastro-
oesophageal cancer patients to the cohort increased the
overall surgery rates to 18.2%.
The majority of oesophageal cancer patients who
underwent resection were <70 years (71%), male (76%),
Table 1 Characteristics of patients diagnosed with
oesophageal (C15) and gastro-oesophageal cancer (C160)
Variable C15 C160 C15 & C160
N=3,456 N=1,568 N=5,024
n % n % n %
Age at diagnosis
group (years)
<60 657 19.0 402 25.6 1,059 21.1
60–69 840 24.3 399 25.4 1,239 24.7
70–79 1,048 30.3 486 31.0 1,534 30.5
80+ 911 26.4 281 17.9 1,192 23.7
Gender
Female 1,159 33.5 362 23.1 1,521 30.3
Male 2,297 66.5 1,206 76.9 3,503 69.7
Country of Birth
Australia 2,497 72.2 1,063 67.8 3,560 70.9
Other 959 37.8 505 32.2 1,464 29.1
Histology group
SCC 1,478 42.8 70 4.5 1,548 30.8
Adenocarcinomas 1,549 44.8 1,398 89.2 2,947 58.7
Other 293 8.5 79 5.0 372 7.4
Degree of Spread
Localised 1,290 37.3 435 27.7 1,725 34.3
Regional 692 20.0 543 34.6 1,235 24.6
Distant 622 18.0 387 24.7 1,009 20.1
Unknown 721 20.9 203 12.9 924 18.4
Tumour location
Upper 297 8.6 297 5.9
Middle 470 13.8 470 9.4
Lower 1,528 45.0 1,528 30.9
NOS* 1,113 32.7 1,113 22.2
GOJ* 1,568 1,568 31.2
Charlson comorbidity
0 3,098 89.6 1,431 91.2 4,529 90.1
1,2 331 9.6 124 7.9 455 9.1
3+ 27 0.8 13 0.8 40 0.8
*NOS = not otherwise specified; GOJ = gastro-oesophageal junction.
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(70%) and were diagnosed with adenocarcinoma (62%)
and with loco-regional disease at the time of notification
(85%). Gastro-oesophageal cancer patients had even
higher proportions of males (87%) and adenocarcinoma
patients (93%) who underwent resection. After adjust-
ment for covariates, surgical resection for oesophageal
cancer patients was associated with younger age
(p<0.001), adenocarcinoma (p<0.001), non-metastatic
disease (p<0.001), no pre-existing comorbidity (p=0.006)and the resection being conducted in a public or private
co-located hospital (p<0.001) (Table 2). Not surprisingly
the addition of gastro-oesophageal patients to the cohort
increased patient numbers and resulted in some add-
itional significant predictors of surgical resection (male
gender [aOR=1.31 95%CI 1.05-1.64], born in Australia
[aOR=1.32, 95%CI 1.09-1.61] and undergoing surgery at
specific area health services).Sub-analyses of patients with non-metastatic
adenocarcinoma
When restricted to the 2,155 non-metastatic adenocar-
cinoma patients, the addition of gastro-oesophageal can-
cer patients increased the overall surgery rate to 29.6%
(from 26.1% for oesophageal cancer alone). Patient and
hospital factors associated for surgery in this sub-cohort
were the same as the entire cohort. The addition of the
gastro-oesophageal patients again added the significant
predictors of surgical resection (male gender [aOR=2.03
95%CI 1.44-2.85], being born in Australia [aOR=1.41,
95%CI 1.35-3.44] and undergoing surgery at specific area
health services).Outcomes following surgery (Table 4)
Rates of hospital length-of-stay >28 days (20.9% and
19.7%), 30-day mortality (3.8% and 2.7%) and one-year
cancer survival (75.5% and 76.9%) were similar for
oesophageal cancer and the combined cohort respect-
ively, but differed by 4.5% for 30-day complication rates
(21.5% and 17.0%). Mean one year survival time for the
combined cohort was 328 days (SD 48 days).
When investigating the factors associated with longer
length of hospital stay and one-year survival, the inclu-
sion of cancer of the gastro-oesophageal junction did not
alter the trends established with that of oesophageal can-
cer alone. However, due to increased precision, some of
the associations that were not statistically significant in
oesophageal cancer alone became significant in the over-
all cohort. For longer length of stay these factors were:
being Australian born (aOR=1.49, 95%CI 1.01-2.17) and
having surgery in a public co-located hospital (aOR=2.10,
95%CI 1.17-3.78). Other factors associated with length
of stay >28 days included older age (p<0.001), having
an admission in a public hospital (p<0.001) and not
being admitted in certain area health services. Poorer
survival in the overall cohort was associated with older
age (p<0.001) and private non-co-located hospitals
compared with private co-located hospitals (aHR=2.20,
95%CI 1.03-4.70).
We did not observe any significant associations for
30 day post-resection complication in the overall cohort.
However, in the oesophageal cohort we found older age
and some area health services were associated with
Table 2 Patient characteristics, location and surgery type
of cohort who received resection
Variable C15 C160 C15 & C160
N=3,456 N=1,568 N=5,024
n % n % n %
Oesophagectomy Yes 503 14.6 412 26.3 915 18.2
PATIENT CHARACTERISTICS
Age at diagnosis (years)
<60 164 4.7 137 8.7 301 6.0
60–69 195 5.6 137 8.7 332 6.6
70–79 116 3.4 120 7.7 236 4.7
80+ 28 0.8 18 1.1 46 0.9
Gender
Female 118 3.4 54 3.4 172 3.4
Male 385 11.1 358 22.8 743 14.8
Country of Birth
Australia 345 10.0 291 18.6 636 12.7
Other 158 4.6 121 7.7 279 5.6
Histology group
SCC 169 4.9 12 0.8 181 3.6
Adenocarcinomas 312 9.0 385 24.6 697 13.9
Other 11 0.3 11 0.7 22 0.4
Degree of Spread
Localised 197 5.7 123 7.8 320 6.4
Regional 232 6.7 239 15.2 471 9.4
Distant 38 1.1 35 2.2 73 1.5
Unknown 36 1.0 15 1.0 51 1.0
Tumour location
Upper 17 0.5 17 0.3
Middle 55 1.6 55 1.1
Lower 331 9.6 331 6.6
NOS* 99 2.9 99 2.0
GOJ* 412 26.3 412 8.3
Charlson comorbidity
0 353 10.2 284 18.1 637 12.7
1,2 32 0.9 22 1.4 54 1.1
3+ 0 0.0 2 0.1 2 0.0
HOSPITAL CHARACTERISTICS
Surgery type
Abdothoracic 79 2.3 65 4.1 144 2.9
Abdocervical 64 1.9 45 2.9 109 2.2
Transhiatal 360 10.4 301 19.2 661 13.2
Hospital admission
Private co-located 97 2.8 75 4.8 172 3.4
Private non co-located 90 2.6 87 5.5 177 3.5
Public co-located 182 5.3 131 8.4 313 6.2
Public non co-located 134 3.9 119 7.6 253 5.0
Table 2 Patient characteristics, location and surgery type
of cohort who received resection (Continued)
Hospital area service
Area 1 99 2.9 90 5.7 189 3.8
Area 2 107 3.1 85 5.4 192 3.8
Area 3 93 2.7 70 4.5 163 3.2
Area 4 126 3.6 90 5.7 216 4.3
Area 5 53 1.5 51 3.3 104 2.1
Area 6 11 0.3 9 0.6 20 0.4
Area 7 14 0.4 17 1.1 31 0.6
Area 8 0 0.0 0 0.0 0 0.0
* NOS = not otherwise specified; GOJ = gastro-oesophageal junction.
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nificance in the overall cohort may be attributed to the
lower complication rate with gastro-oesophageal cancer.
The small number of patients dying within 30-days of
surgery did not permit us to perform adjusted analysis
for this outcome measure.
Outcomes following surgery in patients with non-
metastatic adenocarcinoma
Rates of hospital length-of-stay >28 days (17.3% and
19.6%), 30-day mortality (2.4% and 2.8%), 30-day compli-
cation rates (19.0% and 19.7%) and one-year cancer sur-
vival (80.6% and 79.7%) were similar for patients with
non-metastatic adenocarcinoma oesophageal cancer and
the combined cohort respectively.
Factors associated with poorer post-resection out-
comes in the sub-cohort were similar to those reported
in all patients. However, in this group of patients with
non-metastatic adenocarcinoma, we did not observe any
significant associations for 30-day post-resection compli-
cation in the combined cohort or in oesophageal cancer
alone.
Discussion
There is an increasing use of health administrative data
for research and in health policy and planning. We
examined rates of oesophagectomy on oesophageal can-
cer patients and whether the inclusion of patients with
gastro-oesophageal cancer affected oesophagectomy rates
and post-resection outcomes in NSW. Unsurprisingly,
the addition of gastro-oesophageal cancer patients to our
cohort increased the oesophagectomy rates by 3.5%.
Clearly if hospital funding is based partly on patient
admissions and the volume of procedures undertaken,
care must be taken to ensure that all potential ‘qualifying’
patients are included in any performance assessment.
Our reported rate of oesophagectomy in patients is com-
parable to previously reported European and UK studies
[30,31] However, the UK rate has been decreasing [38]
Table 3 Surgery rates and factors associated with receiving surgery by topography
Variable C15 Surgical Rate
(per 100)
aOR# (95%CI) C15&C160 Surgical
rate (per 100)
aOR (95% CI) #
Age at diagnosis (years)
<60 25.0 8.96 (5.63-14.3)* 28.4 8.12 (5.64-11.7)*
60–69 23.2 9.85 (6.25-15.5)* 26.8 8.48 (5.94-12.1)*
70–79 11.1 3.99 (2.52-6.32)* 15.4 4.20 (2.94-6.00)*
80+ 3.1 Referent 3.9 Referent
Gender
Female 10.2 Referent 11.3 Referent
Male 16.8 1.04 (0.78-1.38) 21.2 1.31 (1.05-1.64)*
Country of Birth
Australia 13.8 Referent 17.9 Referent
Other 16.5 0.90 (0.70-1.16) 19.1 0.76 (0.62-0.92)*
Histology group
SCC 11.4 0.40 (0.31-0.52)* 11.7 0.41 (0.32-0.51)*
Adenocarcinomas 20.1 Referent 23.6 Referent
Other 3.8 0.28 (0.17-0.48)* 5.9 0.36 (0.24-0.53)*
Degree of Spread
Localised 15.3 6.06 (4.06-9.06)* 18.6 5.50 (4.08-7.41)*
Regional 33.5 12.34 (8.22-18.52)* 38.1 10.29 (7.67-13.79)*
Distant 6.1 Referent 6.4 Referent
Unknown 5.0 2.38 (1.42-3.98)* 5.5 1.71 (1.14-2.56)*
Tumour location
Upper 5.8 0.22 (0.12-0.39) 5.8 0.22 (0.13-0.40)
Mid 10.9 0.51 (0.34-0.76) 10.9 0.52 (0.35-0.77)
Distal 21.5 Referent 21.5 26.4 Referent 1.10 (0.88-1.36)
Charlson comorbidity
0 11.4 Referent 14.1 Referent
1,2 9.7 0.52 (0.32-0.83)* 11.9 0.56 (0.39-0.80)*
3+ 0 - 5.0 0.25 (0.06-1.14)
Hospital admission
Private co-located 43.1 Referent 46.5 Referent
Private non co-located 4.4 0.06 (0.04-0.10)* 6.2 0.07 (0.05-0.10)*
Public co-located 34.0 0.78 (0.53-1.16) 37.8 0.80 (0.59-1.08)
Public non co-located 20.6 0.26 (0.16-0.42)* 26.5 0.26 (0.18-0.38)*
Hospital area service
Area 1 18.1 2.30 (1.38-3.84)* 23.6 2.99 (2.03-4.39)*
Area 2 16.2 0.73 (0.48-1.09) 19.4 0.80 (0.59-1.09)
Area 3 25.8 Referent 28.6 Referent
Area 4 19.6 1.29 (0.86-1.93) 23.8 1.58 (1.16-2.17)*
Area 5 12.2 1.71 (0.99-2.97) 16.5 1.92 (1.27-2.90)*
Area 6 3.5 0.82 (0.38-1.77) 4.6 0.88 (0.49-1.56)
Area 7 5.1 0.71 (0.34-1.47) 8.2 0.98 (0.59-1.65)
Area 8 0.0 - 0.0 -
# Adjusted for age-group, gender, histology, country of birth, histology, degree-of-spread, tumour location, hospital admitted, area of service, Charlson comorbidity index.
* Significant at P<0.05 (two-tailed) level.
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Table 4 Patient and hospital factors associated with outcomes following surgical resection
C15 C15 & C16.0
Outcome N (Rate per 100) aOR (95%CI)# N (Rate per 100) aOR (95%CI) #
(i) Length-of-stay >28 days 105 (20.9) 186 (19.7)
<60 years 23 (14.0) 0.20 (0.08-0.53)* 43 (14.3) 0.24 (0.12-0.51)*
60–64 years 43 (22.1) 0.41 (0.17-1.00) 67 (20.2) 0.43 (0.22-0.87)*
70–74 years 28 (24.1) 0.44 (0.17-1.13) 60 (25.4) 0.57 (0.28-1.17)
80+ years 11 (39.3) Referent 16 (34.8) Referent
Australian born 75 (21.7) Referent 133 (20.9) Referent
Overseas born 30 (19.0) 0.62 (0.38-1.05) 53 (19.0) 0.67 (0.46-0.99)*
Private co-located 14 (14.4) Referent 22 (12.8) Referent
Private non co-located 11 (12.2) 1.06 (0.43-2.63) 23 (13.0) 1.92 (0.90-4.13)
Public co-located 43 (23.6) 1.61 (0.74-3.49) 71 (22.7) 2.10 (1.17-3.78)*
Public non co-located 37 (27.6) 3.16 (0.98-10.8) 70 (27.7) 7.89 (3.16-19.5)*
Area 1 29 (29.3) 0.91 (0.26-3.18) 52 (27.5) 0.44 (0.17-1.10)
Area 2 22(20.6) 0.91 (0.43-1.96) 43 (22.4) 1.24 (0.70-2.19)
Area 3 22 (23.7) Referent 37 (22.7) Referent
Area 4 21 (16.7) 0.74 (0.33-1.66) 33 (15.3) 0.64 (0.34-1.20)
Area 5 8 (15.1) 0.30 (0.07-1.26) 14 (13.5) 0.15 (0.05-0.43)*
Area 6 2 (18.2) 0.82 (0.12-5.59) 3 (15.0) 0.30 (0.07-1.39)
Area 7 1 (7.1) 0.18 (0.02-1.92) 4 (12.9) 0.22 (0.06-0.86)*
(ii) 30 day complication 108 (21.5) 168 (17.0)
<60 years 35 (21.3) 0.40 (0.17-0.98)* 53 (17.6) 0.53 (0.26-1.10)
60–64 years 36 (18.5) 0.33 (0.14-0.80)* 59 (17.8) 0.55 (0.27-1.13)
70–74 years 25 (21.6) 0.39 (0.16-0.99)* 52 (22.0) 0.70(0.34-1.46)
80+ years 12 (42.9) Referent 14 (30.4) Referent
Australian born 71 (20.6) Referent 129 (20.3) Referent
Overseas born 37 (23.4) 1.28 (0.79-2.08) 49 (17.6) 0.87 (0.92-1.06)
Private co-located 16 (16.5) Referent 28 (16.3) Referent
Private non co-located 22 (24.4) 1.13 (0.43-2.98) 32 (18.1) 1.07 (0.51-2.23)
Public co-located 40 (22.0) 1.82 (0.87-3.78) 61 (19.5) 1.37 (0.79-2.40)
Public non co-located 30 (22.4) 0.74 (0.23-2.37) 57 (22.5) 1.47 (0.62-3.49)
Area 1 25 (25.3) 3.88 (1.12-13.5)* 40 (21.2) 1.36 (0.54-3.47)
Area 2 21 (19.6) 1.91 (0.85-4.28) 37 (19.3) 1.40 (0.76-2.57)
Area 3 15 (16.1) Referent 28 (17.2) Referent
Area 4 29 (23.0) 2.24 (0.99-5.09) 40 (18.5) 1.29 (0.68-2.42)
Area 5 13 (24.5) 4.01 (1.04-15.4)* 23 (22.1) 1.34 (0.49-3.65)
Area 6 9 (18.2) 2.86 (0.43-19.1) 2 (10.0) 0.74 (0.14-3.97)
Area 7 11 (21.4) 3.87 (0.68-22.1) 8 (25.8) 2.14 (0.66-6.91)
Mortality N (rate per 100) aHR (95%CI) Mortality N (rate per 100) aHR (95%CI)
(iv) One year survival 123 (24.5) 218 (23.1)
<60 years 36 (22.0) 0.20 (0.10-0.41)* 64 (21.3) 0.41 (0.23-0.74)*
60–64 years 38 (30.9) 0.19 (0.09-0.38)* 65 (19.6) 0.36 (0.20-0.65)*
70–74 years 32 (27.6) 0.22 (0.10-0.47)* 68 (28.8) 0.44 (0.24-0.81)*
80+ years 17 (60.7) Referent 21 (45.6) Referent
Australian born 90 (26.1) Referent 155 (24.4) Referent
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Table 4 Patient and hospital factors associated with outcomes following surgical resection (Continued)
Overseas born 33 (20.9) 0.64 (0.39-1.06) 63 (22.6) 0.74 (0.51-1.08)
Private co-located 10 (10.3) Referent 20 (11.6) Referent
Private non co-located 22 (24.4) 1.58 (0.57-4.42) 40 (22.6) 2.20 (1.03-4.70)*
Public co-located 48 (26.4) 1.25 (0.55-2.83) 80 (25.6) 1.80 (0.97-3.32)
Public non co-located 43 (32.1) 1.34 (0.45-4.02) 78 (30.8) 1.66 (0.71-3.89)
Area 1 34 (34.3) 1.06 (0.36-3.16) 61 (32.3) 1.28 (0.54-3.03)
Area 2 23 (21.5) 0.93 (0.42-2.04) 41 (21.4) 1.08 (0.60-1.96)
Area 3 25 (26.9) Referent 38 (23.3) Referent
Area 4 19 (15.1) 0.73 (0.32-1.68) 38 (17.6) 0.93 (0.49-1.76)
Area 5 15 (28.3) 0.85 (0.26-2.82) 30 (28.9) 1.67 (0.67-4.11)
Area 6 2 (18.2) 1.52 (0.27-8.52) 5 (25.0) 1.92 (0.59-6.22)
Area 7 5 (35.7) 1.45 (0.36-5.87) 5 (16.1) 0.76 (0.22-2.66)
# Adjusted for age-group, gender, histology, country of birth, degree-of-spread, tumour location, hospital admitted, area of service, Charlson comorbidity index, surgery
type.
* Significant at the P<0.05 (two-tailed) level.
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operative assessment and management required for con-
ducting an oesophagectomy [39,40], and the support for
centralization of oesophagectomies being performed in
dedicated multidisciplinary centres [41,42].
Due to increased precision, the inclusion of gastro-
oesophageal cancer resulted in an increase in the number
of predictor variables associated with rates of resection
and post-resection outcomes that were not seen with
oesophageal cancer alone (with the exception of 30-day
complication rates). For our overall cohort, factors asso-
ciated with receiving an oesophagectomy included patient
characteristics (age, gender, birthplace) cancer characteris-
tics (histology, disease spread) and hospital related factors
(location and funding sector); similar to previously pub-
lished work [31]. 30-day mortality in this study was low,
in-line with previous studies and international bench-
marks [9,38,43]. We found that patients undergoing sur-
gical resection in public hospitals were more likely to
have a length of stay >28 days. This may reflect the epi-
demiology of oesophageal and gastro-oesophageal cancer
and that more complex cases are treated in public hospi-
tals (teaching hospitals linked to academic centres in
Australia). Thus, the addition of gastro-oesophageal can-
cer did impact on factors associated with receiving an
oesophagectomy and on some post-surgery outcomes.
One-year cancer survival was worse in those who
underwent surgery in private hospitals that were not co-
located with public hospitals, potentially indicating the
benefits of surgery being conducted in higher volume or
teaching hospitals [7,9,18,21,30,41,44,45].
Our current study demonstrated a reduced 30-day
complication rate in gastro-oesophageal cancer compared
with oesophageal cancer, hence statistical associations
tended towards the null in the combined cohort. Thismay have been due to the slightly higher rate of transhiatal
oesophagectomies undertaken for adenocarcinoma, com-
pared with that in oesophageal cancer and hence lower
peri-operative morbidity [46], however the only factors
which were significantly associated with higher complica-
tion rate in patients with oesophageal cancer were older
age and resection being conducted in some area health
services.
Although we attempted to account for comorbidity
with the use of the CCI, the proportion of patients with
comorbidity preceding cancer diagnosis was low and as
aforementioned, due to how CCI is calculated, comor-
bidity was most likely under-ascertained. The under-
reporting of comorbidities in administrative data may
be due to incomplete data transposition from medical
records in individual hospitals to administrative data-
bases [47-49]. Further, non-surgical treatments such as
chemotherapy and radiotherapy are funded by the PBS
and MBS respectively and this data is not linked rou-
tinely to hospital morbidity data thus it was not available
for this population linkage study. Further, the only mea-
sure of disease severity available was degree-of-spread at
diagnosis; there were no indicators of performance status
available.
Conclusion
Oesophagectomy in NSW is performed with good out-
comes. Our own experience highlights the need for
identifying the appropriate patient populations under
study and their unique contributions to the overall cohort,
given the change in surgical resection rate and longer
length-of-stay post-resection with the inclusion of gastro-
oesophageal cancer. The measurement of hospital per-
formance is a powerful tool to stimulate quality im-
provement, transparency and accountability and health
Stavrou et al. BMC Health Services Research 2012, 12:384 Page 9 of 10
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activity.
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